Expression and Clinical Significance of DNA Demethylase TET in the Tissues in Patients with Neuroblastoma
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2022.0106
- VernacularTitle:DNA去甲基化酶TET在神经母细胞瘤患者中表达及意义
- Author:
Yang YANG
1
;
Feng-yu YANG
1
;
Xiao-yan ZHANG
1
;
Jie-ye HUANG
1
;
Ti ZHOU
1
;
Wei-wei QI
1
;
Yan ZOU
2
;
Xia YANG
1
Author Information
1. Department of Biochemistry and Molecular Biology， Zhongshan School of Medicine， Sun Yat-sen University， Guangzhou 510080， China
2. Guangzhou Women and Children’s Medical Center， Guangzhou 510623， China
- Publication Type:Journal Article
- Keywords:
DNA demethylase TET;
neuroblastoma;
biomarker
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2022;43(1):43-50
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo detect the expression level of DNA demethylase ten eleven translocation TET1， TET2， TET3 in the tissues of neuroblastoma （NB） patients，and to explore the expression and clinical significance of TET in patients with neuroblastoma. MethodsImmunohistochemistry （IHC） was used to detect the expression levels of TET1， TET2 and TET3 in the tissues of 46 patients with neuroblastoma； clinical data from Target database were used to analyze the relationship between the expression of TET1， TET2， TET3 and prognosis of NB patients， and batch correlation analysis was conducted. SPSS 25.0 statistical software was used for analysis， and GraphPad Prism 8 was used for plotting. Results①Immunohistochemical results showed that the expression of TET3 in neuroblastoma patients with different levels of mitosis karyorrhexis index （MKI） was significantly different with statistical significance （P=0.037）. The expression level of TET3 was statistically different among different groups of tumor cell differentiation （P=0.041）， and high expression of TET3 was positively correlated with good prognosis of patients （P=0.020）. The expression of TET1 was positively correlated with the expression of β2-AR （r=0.347， P=0.023）. ②Bioinformatics analysis showed that the mRNA expression level of TET3 was positively correlated with the mRNA expression level of tumor suppressor genes such as activity-dependent neuroprotective protein （ADNP， a neuroprotective protein） and AT-rich interactive domain 2 （ARID2， a chromatin remodeling factor）， and negatively correlated with the mRNA expression level of oncogenes such as CD63 （fourth transmembrane protein） and Josephin domain-containing protein 2 （JOSD2， deubiquitination enzyme）. TARGET database showed that TET3 mRNA level was positively correlated with overall survival （OS） and event-free survival （EFS） of neuroblastoma patients （P=0.024， P=0.014）. ConclusionsThe expression of TET3 in NB patients has a certain relationship with the clinical features of neuroblastoma patients， and the high expression of TET3 is positively correlated with the good prognosis of NB patients， suggesting that TET3 may play a role as a tumor suppressive factor in neuroblastoma， and TET3 can be used as a potential indicator to predict the prognosis of NB patients. It has some value in the clinical evaluation of NB.
